Obstructive sleep apnoea (OSA) is a significant health issue. Patients with cardiovascular disease as well as patients with diabetes have a high prevalence of OSA, and the prevalence of coronary heart disease, heart failure, stroke and diabetes is increased in patients with obstructive sleep apnoea. Physiological responses to OSA include sympathetic activation, neurohumoral changes and inflammation, all of which are precursors for cardiovascular disease and diabetes. International guidelines are starting to recognise the importance of OSA for patients with cardiovascular conditions such as heart failure and hypertension. Diagnosis is important, and home-based sleep testing devices can facilitate this process. Treating OSA with continuous positive airway pressure (CPAP) has been shown to reduce blood pressure (BP) in patients with hypertension, but more research is needed to determine which components of the metabolic syndrome respond best to the addition of CPAP therapy.
Introduction
The first major epidemiological study reporting the prevalence of obstructive sleep apnoea syndrome (OSAS), which is the presence of obstructive sleep apnoea (OSA) in combination with excessive sleepiness, was published by Young et al in 1993. 1 OSA was documented in 2 % of middle-aged women and 4 % of middle-aged men. Later studies showed that OSA was even more common in the general population, with an overall prevalence of more than 20 % in men and 10 % in women, half of whom have moderate to severe sleep-disordered breathing. 2 In 2000,
four studies were published that demonstrated associations between OSA and hypertension. [3] [4] [5] [6] These were the first well-designed analyses conducted in large patient populations which showed the significant negative health effects of obstructive sleep apnoea. Since then, evidence for connections between OSA and numerous comorbidities has continued to grow. Interestingly, the presence of SDB in other cardiovascular diseases was found to be even higher than that in the general population for those aged 30-80 years. 7 The medical consequences of OSA are currently attributed to complex interactions between five different factors -disturbed sleep, intrathoracic pressure swings, intermittent hypoxia, sympathetic activation and the mechanical consequences of snoring, resulting in a range of symptoms (see Figure 1 ).
Much research has been done on OSA in relation to car-accidents, and road, rail and air transport. It is well documented that timely and effective OSA treatment reduces motor vehicle crash risk. 8 For this, and a wide variety of other reasons, sleep apnoea is widely considered to be a serious public health concern. 9 In the last decade, treatment for OSA began to be considered to have potential beneficial cardiovascular effects, in addition to relief of daytime sleepiness. Research shows an increased prevalence of coronary heart disease, heart failure, stroke and diabetes in patients with an apnoea-hypopnoea index (AHI) of five or more per hour. [10] [11] [12] [13] [14] Weight loss, upper airway surgery and, in severe cases, tracheotomy The severity of OSA is defined by the AHI. In adults an AHI of 5-15 
Obstructive Sleep Apnoea, Obesity and Insulin Resistance
Central obesity leads to insulin resistance 34 and is a confounding factor in assessing the independent role of OSA in metabolic syndrome.
Cross-sectional studies, however, provide a growing body of evidence for a positive and independent association between OSA and both insulin resistance/glucose intolerance and diabetes. [35] [36] [37] [38] OSA causes surges in sympathetic overactivity during apnoeic events leading to increased sympathetic tone during the day, as has been shown by muscle sympathetic nerve activity and catecholamine output. 39-42 (see Figure 1 ). This affects other metabolic factors, including the reninangiotensin system, insulin and adiponectin, which may all contribute to insulin resistance. During CPAP treatment in randomised controlled trials, mean arterial blood pressure could be reduced by 2.5 to 10 mmHg. 16, [58] [59] [60] [61] [62] [63] [64] In these trials there appeared to be a relationship between OSA and blood pressure, with greater reductions in those with more severe obstructive sleep apnoea. 
Obstructive Sleep Apnoea and Cancer
OSA has also been linked with cancer in the first study to investigate this association. 67 The severity of OSA was independently correlated with an increased risk of incidence cancer, with hypoxia being the most likely pathologic link. However, the association appeared to be limited to males aged <65 years. 67 Additional studies are required in this area to verify these potentially important findings and to investigate the potential role or influence of CPAP therapy.
Screening and Diagnosis of Obstructive Sleep Apnoea in Metabolic Syndrome Patients
When patients present with classical symptoms such as witnessed apnoeas, heavy snoring or daytime sleepiness there should be no delay in screening for OSA. Different questionnaires are used for identifying patients who need further OSA evaluation. The Berlin Questionnaire was specifically designed for the identification of patients in the general population likely to have OSAS, 68 but while it is useful in the general population, it has not been shown to be useful in the presence of cardiovascular disease. The Epworth Sleepines Scale (ESS) is intended to measure daytime sleepiness. 69 Alternative approaches to OSA diagnosis are being developed in the form of portable monitors. Home sleep testing devices facilitate evaluation for a definitive diagnosis. A recent review of published articles discussed the performance of ApneaLink TM (see Figure 3 ) compared with polysomnography (PSG). 70 ApneaLink TM showed high diagnostic accuracy at AHI cut-off values of 10 (pooled sensitivity 93.3 %, specificity 90.7 %) and 15 (pooled sensitivity 91.4 %, specificity 93.8 %).
Until relatively recently, the standard approach to OSA diagnosis was in-laboratory, technician-attended polysomnography (PSG), which monitors sleep, respiration, cardiac rhythm, snoring, limb movements and body position. 71 Polysomnography, however, is labour-intensive, time-consuming and limited in its availability. This is why many countries have already changed their practice to home-based sleep testing to reduce the number of patients with OSA who go undiagnosed.
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Continuous Positive Airway Pressure Treatment
Continuous Positive Airway Pressure alleviates OSA and therefore reduces nocturia, and improves sleep quality, cognitive function, depression and quality of life. 73, 74 Improvements have also been shown in erectile dysfunction. 75 Continuous Positive Airway Pressure reduces sympathetic drive in OSA patients and thus lowers blood pressure during sleep. 76 The effect this has on daytime blood pressure is variable.
Three meta-analyses looking at the effect of CPAP on blood pressure in OSA showed an average 24-hour reduction in mean arterial pressure of 2 mmHg. 58, 59, 62 The effects varied from no decrease up to a reduction of 10 mmHg. 16, 17 Different inclusion criteria, particularly with respect to the severity of sleep apnoea, the inclusion of normotensive patients and the presence of symptoms of daytime sleepiness, are probably the reasons for the large differences in results between studies. The biggest effects have been shown in patients with resistant hypertension.
In this cohort, OSA prevalence can be as high as 80 %. 77, 78 Interestingly, a recent study showed improvements in sleep apnoea severity after renal sympathetic nerve ablation for resistant hypertension. 79 Two randomised trials evaluating the effect of CPAP therapy in patients with OSA and heart failure (HF) showed significant improvements in left ventricular ejection fraction (LVEF) after one and three months.
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In addition, improvements in quality of life and reduced sympathetic activity were documented. The existing data on OSA in CVD have led to a recommendation in the 2008 HF guidelines stating that OSA should be screened for and, if present, be treated with CPAP in patients with HF. 80 Treatment of OSA with CPAP can alleviate nocturnal myocardial ischaemia. 81 The benefit of CPAP therapy for other metabolic syndrome components appears to be variable, with some studies showing an immediate beneficial treatment effect, persisting over three to six months, and 78 Factors contributing to variability in the benefits of CPAP treatment benefit may be the severity of OSA, obesity and lipid abnormalities, small study populations and lack of rigour in controlled trials. More research needs to be done on which patient subgroups exhibiting one or more components of MetS will benefit from CPAP treatment.
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Compliance is crucial for any therapy to be successful, and early compliance with CPAP therapy is the most important factor. In addition, pre-treatment with drugs may play an important role.
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Current technological improvements in devices and masks (see Figure 4 ) can ensure compliance rates of >80 %. 
